サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：抗リウマチ薬の世界市場：業界動向、シェア、規模、成長、機会、予測（2021年～2026年）
市場調査レポート
商品コード
1046065

抗リウマチ薬の世界市場：業界動向、シェア、規模、成長、機会、予測（2021年～2026年）

Anti-Rheumatics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 145 Pages | 納期: 2～3営業日
AI翻訳ツール 提供対象
ご購入後の翻訳ツール提供について

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
抗リウマチ薬の世界市場：業界動向、シェア、規模、成長、機会、予測（2021年～2026年）
出版日: 2021年12月10日
発行: IMARC Services Private Limited
ページ情報: 英文 145 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の抗リウマチ薬の市場規模は、2015年から2020年にかけて緩やかな成長を示しました。2021年から2026年にかけて市場は約4%のCAGRで成長すると予想されています。

関節リウマチの罹患率の増加は、世界的に抗リウマチ薬の需要を高める主な要因の一つとなっています。さらに、バイオシミラーや新規の生物学的治療法の開発が進んでいることも、市場の見通しを良好にしています。また、世界中で抗リウマチ薬が容易に入手できることに対する大衆の認識が高まっていることも市場に影響を与えています。その他、医療費の大幅な増加やライフサイエンス産業の成長などの重要な要因も市場を牽引すると予測されます。

当レポートでは、世界の抗リウマチ薬市場について調査しており、市場分析、価格分析、競合情勢など、包括的な情報を提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の抗リウマチ薬市場

  • 市場概要
  • 市場パフォーマンス
  • COVID-19の影響

第6章 市場セグメンテーション：タイプ別

  • 処方薬
  • 市販薬

第7章 市場セグメンテーション：医薬品クラス別

  • 疾患修飾性抗リウマチ薬（DMARD）
  • 非ステロイド性抗炎症薬（NSAID）
  • コルチコステロイド
  • 尿酸薬
  • その他

第8章 市場セグメンテーション：薬物投与経路別

  • 経口
  • 非経口
  • その他

第9章 市場セグメンテーション：流通経路別

  • 病院薬局
  • 小売薬局
  • Eコマース

第10章 市場セグメンテーション：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東とアフリカ
    • 市場セグメンテーション：国別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Celltrion Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnsons
    • Pfizer Inc.
    • Sanofi SA
目次
Product Code: SR1020H124_Report

The global anti-rheumatics market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Anti-rheumatics refers to drugs used to treat different symptoms of rheumatoid arthritis. These drugs are also utilized for treating inflammatory myositis and bowel diseases, various types of cancers, and connective tissue diseases, such as systemic sclerosis (SSc), systematic lupus erythematosus (SLE), and Sjogren syndrome (SS). They can be administered orally, subcutaneously (SC) or intravenously (IV) into the body. They assist in decreasing inflammation, preventing joint damage, reducing pain and swelling, and slowing the progression of arthritis. As a result, anti-rheumatics are increasingly being prescribed by specialists like rheumatologists, gastroenterologists or dermatologists across the globe.

Anti-Rheumatics Market Trends:

  • Rheumatoid arthritis is an inflammatory disease that causes swelling and pain in joints. It can also damage the skin, eyes, lungs, heart, and blood vessels. Therefore, the increasing prevalence of this medical condition represents one of the primary factors catalyzing the demand for anti-rheumatics around the world. These drugs aid in preventing bone deformity and improving overall body functions. As a result, their demand is escalating among the geriatric population, which is relatively more prone to these diseases. Furthermore, the growing development in the field of biosimilars and novel biologic therapies are creating a favorable market outlook. These therapies target individual molecules and act faster compared to conventional drugs. They are usually provided in combination with the disease-modifying anti-rheumatic drug (DMARD) to patients who have not responded to other treatments. The market is also influenced by the rising awareness among the masses about the easy availability of anti-rheumatics worldwide. Other significant factors, including a considerable rise in healthcare expenditure and extensive growth in the life sciences industry, are projected to drive the market.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-rheumatics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, drug class, route of drug administration and distribution channel.

Breakup by Type:

  • Prescription-based Drugs
  • Over-the-Counter Drugs

Breakup by Drug Class:

  • Disease Modifying Anti-Rheumatics Drugs (DMARD's)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

Breakup by Route of Drug Administration:

  • Oral
  • Parenteral
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Bristol-Myers Squibb Company, Celltrion Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnsons, Pfizer Inc. and Sanofi SA. Key Questions Answered in This Report:

  • How has the global anti-rheumatics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global anti-rheumatics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the route of drug administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global anti-rheumatics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Rheumatics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription-based Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-Counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Disease Modifying Anti-Rheumatics Drugs (DMARD's)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Corticosteroids
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Uric Acid Drugs
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Route of Drug Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Parenteral
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 E-Commerce
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bristol-Myers Squibb Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Celltrion Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 F. Hoffmann-La Roche AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
    • 15.3.9 Johnson & Johnsons
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi SA
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis